(Q42786117)

7 November 2017

title

Zoledronic acid in myeloma: MRC Myeloma IX. (English)

1 reference

7 November 2017

1 reference

S Vincent Rajkumar

1

1 reference

7 November 2017

language of work or name

English

0 references

publication date

3 December 2010

1 reference

7 November 2017

1 reference

7 November 2017

volume

376

1 reference

7 November 2017

issue

9757

1 reference

7 November 2017

page(s)

1965-1966

1 reference

Review of 1027 patients with newly diagnosed multiple myeloma

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

Bisphosphonates: mechanism of action and role in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962178-2

7 January 2021

10.1016/S0140-6736(10)62178-2

Identifiers

DOI

1 reference

7 November 2017

1 reference